For over two decades, society has been fighting a losing battle against the “epidemic of bullying.” Because we have come to rely on researchers for the solution, but researchers routinely recommend programs despite their poor results, I wrote a piece eight years ago called, “The First Step to Ending the Bullying Crisis.” It maintains that we will never turn the tide in this campaign until researchers begin questioning the bullying orthodoxy.
To my great excitement, a scholarly paper has been published that does exactly that. “Hypotheses for Possible Iatrogenic Impacts of School Bullying Prevention Programs,” by Karyn L. Healy, Ph.D., of the QIMR Berghofer Medical Research Institute, Australia, takes the bold step of highlighting findings that not only don’t most of the prevalent anti-bullying interventions work well, they may even be
Trial begins to solve complicated treatment problem for child cancer
We’re sorry, this service is currently unavailable. Please try again later.
Dismiss
Normal text size
Advertisement
A clinical trial is under way to prove the effectiveness of a new method developed by Queensland scientists to remove the major side-effect of a treatment for cancer and genetic disorders in children.
The trial is expected to involve about 20 children aged between three months and 18 years who need stem cell treatment for blood cancers or genetic immune deficiencies.
Researchers at QIMR Berghofer have developed a method to remove a major side-effect from stem cell therapy, giving hope to hundreds of children with cancers and genetic disorders.
Researchers at the QIMR Berghofer Medical Research Institute in Brisbane have launched a clinical trial of a new cellular immunotherapy treatment. The.
Trial therapy could âturbochargeâ sick kidsâ immune cells A world-first study is underway into a potentially lifesaving therapy for children having stem cell transplants.
Health by Janelle Miles
Premium Content
Subscriber only Queensland researchers have begun a world-first trial of a new treatment aimed at preventing life-threatening infections in children having stem cell transplants. The two-year study of up to 20 children as young as three months old will test whether giving them immunotherapy after their transplant reduces the risk of dangerous viral infections. Two patients at the Queensland Children s Hospital have already received the treatment manufactured at the QIMR Berghofer Medical Research Institute.
QIMR Berghofer Medical Research Institute has entered into a collaborative R&D agreement with Australian start-up company, MedAir Australia, to test a.